During the AGM a shareholder asked why Virbac appeared to hogging the credit for Stelfonta, as there was not even a mention of Qbiotics on the label. It was a query that was swiftly deflected. Perhaps Qbiotics needs to take a lesson from the following, particularly as it is collaborating with Merck
Pandion's secret to moving a $65M Merck offer to a $1.9B done deal in a year? Just keep saying no | FierceBiotech
